Clearline Capital LP Has $2.33 Million Holdings in Enfusion, Inc. (NYSE:ENFN)

Clearline Capital LP grew its position in Enfusion, Inc. (NYSE:ENFN) by 33.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 245,145 shares of the company’s stock after purchasing an additional 61,971 shares during the quarter. Clearline Capital LP owned about 0.19% of Enfusion worth $2,326,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Enfusion by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 3,653,189 shares of the company’s stock worth $33,792,000 after buying an additional 51,670 shares during the period. Impax Asset Management Group plc increased its position in Enfusion by 25.4% during the third quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock worth $6,424,000 after acquiring an additional 136,948 shares during the period. Scalar Gauge Management LLC raised its stake in Enfusion by 21.8% in the 2nd quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock worth $5,227,000 after purchasing an additional 110,000 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Enfusion by 57.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company’s stock valued at $4,466,000 after purchasing an additional 191,436 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Enfusion by 9.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 365,512 shares of the company’s stock worth $3,469,000 after purchasing an additional 31,743 shares in the last quarter. Institutional investors own 81.05% of the company’s stock.

Enfusion Price Performance

Shares of NYSE ENFN opened at $9.94 on Monday. The stock has a market capitalization of $1.28 billion, a PE ratio of 248.50, a P/E/G ratio of 3.72 and a beta of 0.93. Enfusion, Inc. has a fifty-two week low of $7.52 and a fifty-two week high of $10.45. The business has a fifty day moving average price of $9.32 and a two-hundred day moving average price of $8.89.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.